Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories


Intervenn attracts $201m in series C
Intervenn Biosciences was co-founded by faculty members at Stanford University and University of California, Berkeley.
Planted grows with $21m
New and returning investors have chipped into the ETH Zurich plant-based meat spinout’s pre-series B round, five months after it completed a series A.
T-Knife secures $110m in series B
The MDC spinout raised a series B round which will be used to boost its manufacturing capacity and advance its pipeline of candidates.
Everactive tops up series C
The industrial sensor manufacturer spun out of Michigan and Virginia has increased its latest round to $51m in a tranche backed by 3M, Ericsson and Armstrong International.
Icosavax lands on $182m IPO
UW's vaccine development company has listed on Nasdaq, with its shares rising on the first day of trading.
Tenaya tends to $180m IPO
The GV-backed cardiovascular therapeutics company has priced an upsized offering on Nasdaq, with the shares closing just marginally higher on the first day.
Daily deal net: July 30, 2021
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Deep Genomics jumps into $180m series C
University of Toronto-linked Deep Genomics has picked up $180m in its series C round led by SoftBank Vision Fund 2.

News Continued

Niron Magnetics attracts $21.3m
University of Minnesota spinout Niron Magnetics has collected $21.3m in funding to build a pilot production facility for its rare earth-free magnets.
IgGenix initiates $25m series A1
Co-founded by Stanford researchers, IgGenix is working on therapies that address severe allergies.
Tepha ticks acquisition box
Based on research originally conducted at MIT, Tepha has been purchased by BD for an undisclosed sum.
Isar Aerospace increases series B payload
TU Munich spinout Isar Aerospace has added $75m to its series B round, bringing the round’s total to nearly $166m and its overall financing to more than $183m.
Ring circles $117m series B
UPMC Enterprises has contributed to a $117m series B round for gene therapy developer Ring Therapeutics.
Topas tops up series B
Topas Therapeutics has almost doubled its series B round to $48m thanks to an extension backed by all of its shareholders.

Editor's Picks

Aerovate accesses public markets
Less than a year after raising $72.6m in its series A round, Aerovate Therapeutics has gone public following an IPO worth more than $121m.
Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Otsuka takes up Veryan’s acquisition offer
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
test reg